News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lundbeck Inc. (LUN.CO) Halts Sales of Leukemia Drug Over Supply Problems



9/14/2012 7:21:08 AM

H. Lundbeck A/S (LUN.KO) plans to stop selling a leukemia treatment because of manufacturing and supply difficulties. Denmark-based Lundbeck "is no longer in a position to guarantee a future supply" of the drug Elspar, Roger Keding, vice president of supply chain management, said in an Aug. 3 letter to U.S. health-care providers. "Lundbeck has concluded that continuing to manufacture and distribute Elspar is not a sustainable business going forward." The company plans to discontinue Elspar sales globally, and to stop selling Elspar in the U.S. effective Dec. 31; the date could change depending on remaining inventory.

Read at Nasdaq
Read at Wall Street Journal


comments powered by Disqus
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES